GB Sciences (GBLX) 10-Q 9 Nov 22 2022 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Sep. 30, 2022	Nov. 09, 2022
Document Information [Line Items]
Entity Central Index Key	0001165320
Entity Registrant Name	GB SCIENCES INC
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	000-55462
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	59-3733133
Entity Address, Address Line One	3550 W. Teco Avenue
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	866
Local Phone Number	721-0297
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		378,205,894

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2022	Mar. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 657,754	$ 233,893
Prepaid expenses and other current assets	220,727	93,933
TOTAL CURRENT ASSETS	878,481	327,826
Intangible assets, net of accumulated amortization of $144,694 and $104,201 at September 30, 2022 and March 31, 2022, respectively	2,238,971	2,222,074
TOTAL ASSETS	3,117,452	2,549,900
CURRENT LIABILITIES:
Accounts payable	1,581,823	1,657,008
Accrued interest	425,915	384,769
Accrued liabilities	17,071	9,627
Notes and convertible notes payable and line of credit, net of unamortized discount of $18,176 and $1,765 at September 30, 2022 and March 31, 2022, respectively	1,169,919	987,565
Income taxes payable	896,495	896,495
TOTAL CURRENT LIABILITIES	4,091,223	3,935,464
Notes and convertible notes payable, net of unamortized discount of $52,529 and $99,489 at September 30, 2022 and March 31, 2022, respectively	219,597	397,308
TOTAL LIABILITIES	4,310,820	4,332,772
Commitments and contingencies (Note 6)
STOCKHOLDERS' EQUITY/(DEFICIT):
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 378,205,894 and 325,037,557 outstanding at September 30, 2022 and March 31, 2022, respectively	37,821	32,504
Additional paid-in capital	104,160,079	102,764,746
Accumulated deficit	105,391,268	104,580,122
TOTAL STOCKHOLDERS' DEFICIT	(1,193,368)	(1,782,872)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 3,117,452	$ 2,549,900

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2022	Mar. 31, 2022
Intangible assets, accumulated amortization	$ 144,694	$ 104,201
Unamortized discount, current	18,176	1,765
Unamortized discount, noncurrent	$ 52,529	$ 99,489
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	378,205,894	325,037,557
Common stock, shares outstanding (in shares)	378,205,894	325,037,557

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Sales revenue	$ 0	$ 0	$ 0	$ 0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
General and administrative expenses	275,839	411,545	735,357	904,951
LOSS FROM OPERATIONS	(275,839)	(411,545)	(735,357)	(904,951)
OTHER INCOME/(EXPENSE)
Interest expense	(37,218)	(95,244)	(75,789)	(160,498)
Other income	0	9,000	0	9,000
Total other expense	(37,218)	(86,244)	(75,789)	(151,498)
LOSS BEFORE INCOME TAXES	(313,057)	(497,789)	(811,146)	(1,056,449)
Income tax expense	0	0	0	0
LOSS FROM CONTINUING OPERATIONS	(313,057)	(497,789)	(811,146)	(1,056,449)
Loss from discontinued operations	0	(58,067)	0	(131,823)
NET LOSS	(313,057)	(555,856)	(811,146)	(1,188,272)
Net loss attributable to common stockholders of GB Sciences, Inc. - basic and diluted
Continuing operations	(313,057)	(497,789)	(811,146)	(1,056,449)
Discontinued operations	0	(58,067)	0	(131,823)
Net loss	$ (313,057)	$ (555,856)	$ (811,146)	$ (1,188,272)
Net loss per common share – basic and diluted
Continuing operations (in dollars per share)	$ 0	$ 0	$ 0	$ 0
Discontinued operations (in dollars per share)	0	0	0	0
Net loss (in dollars per share)	$ 0	$ 0	$ 0	$ 0
Weighted average common shares outstanding - basic and diluted (in shares)	346,269,298	317,429,078	336,062,449	316,557,100

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
OPERATING ACTIVITIES:
Net loss	$ (811,146)	$ (1,188,272)
Loss from discontinued operations	0	(131,823)
Net loss from continuing operations	(811,146)	(1,056,449)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	40,492	35,085
Stock-based compensation	13,000	39,000
Amortization of debt discount and beneficial conversion feature	30,548	104,499
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(126,794)	36,010
Accounts payable	(102,254)	(30,120)
Accrued expenses	7,444	27,414
Accrued interest	41,146	55,857
Net cash used in operating activities of continuing operations	(907,564)	(788,704)
Net cash provided by operating activities of discontinued operations	0	16,243
Net cash used in operating activities	(907,564)	(772,461)
INVESTING ACTIVITIES:
Proceeds from sale of Nevada subsidiaries	0	200,000
Acquisition of intangible assets	(30,320)	(100,000)
Net cash provided by/(used in) investing activities of continuing operations	(30,320)	100,000
Net cash provided by investing activities of discontinued operations	0	1,502
Net cash provided by/(used in) investing activities	(30,320)	101,502
FINANCING ACTIVITIES:
Gross proceeds from warrant exercises	0	62,660
Proceeds from issuing convertible note	0	50,000
Gross proceeds from issuing common stock	1,595,000	0
Brokerage fees for common stock sales	(207,350)	0
Principal payment on notes and convertible notes payable	(25,905)	0
Net cash provided by financing activities of continuing operations	1,361,745	112,660
Net cash used in financing activities of discontinued operations	0	(67,931)
Net cash provided by financing activities	1,361,745	44,729
Net change in cash and cash equivalents	423,861	(626,230)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	233,893	1,145,633
CASH AND CASH EQUIVALENTS AT END OF PERIOD	657,754	519,403
Less: cash and cash equivalents classified as discontinued operations	0	(124,078)
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS	657,754	395,325
Cash paid for interest	0	0
Cash paid for income tax	0	0
Non-cash investing and financing transactions:
Compensation warrants issued to brokers in private placement	145,150	0
Depreciation capitalized in inventory (discontinued operations)	0	213,425
Accrued patent drafting and filing costs capitalized in intangible assets	27,069	189,880
Accrued brokerage fees for convertible notes and warrant exercises	0	12,776
Stock options issued as compensation for drafting and filing patent applications	0	28,800
Induced dividend from warrant exercises	$ 0	$ 163,017

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity/(Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Mar. 31, 2021	315,340,411
Balance at Mar. 31, 2021	$ 31,534	$ 102,380,770	$ (103,886,232)	$ (1,473,928)
Share based compensation expense		39,000		39,000
Net income (loss)	0	0	(1,188,272)	(1,188,272)
Stock options issued as compensation for drafting and filing patents	$ 0	28,800	0	28,800
Exercise of warrants for stock, net of issuance costs (in shares)	2,088,667
Exercise of warrants for stock, net of issuance costs	$ 209	56,185	0	56,394
Inducement dividend from warrant exercises	$ 0	163,017	(163,017)	0
Balance (in shares) at Sep. 30, 2021	317,429,078
Balance at Sep. 30, 2021	$ 31,743	102,667,772	(105,237,521)	(2,538,006)
Balance (in shares) at Jun. 30, 2021	317,429,078
Balance at Jun. 30, 2021	$ 31,743	102,619,471	(104,681,665)	(2,030,451)
Share based compensation expense		19,501		19,501
Net income (loss)			(555,856)	(555,856)
Stock options issued as compensation for drafting and filing patents	$ 0	28,800	0	28,800
Balance (in shares) at Sep. 30, 2021	317,429,078
Balance at Sep. 30, 2021	$ 31,743	102,667,772	(105,237,521)	(2,538,006)
Balance (in shares) at Mar. 31, 2022	325,037,557
Balance at Mar. 31, 2022	$ 32,504	102,764,746	(104,580,122)	(1,782,872)
Stock issued for cash, net of offering costs (in shares)	53,168,337
Stock issued for cash, net of offering costs	$ 5,317	1,382,333	0	1,387,650
Share based compensation expense		13,000		13,000
Net income (loss)	$ 0	0	(811,146)	(811,146)
Stock options issued as compensation for drafting and filing patents				0
Balance (in shares) at Sep. 30, 2022	378,205,894
Balance at Sep. 30, 2022	$ 37,821	104,160,079	(105,391,268)	(1,193,368)
Balance (in shares) at Jun. 30, 2022	329,205,891
Balance at Jun. 30, 2022	$ 32,921	102,879,579	(105,078,211)	(2,165,711)
Stock issued for cash, net of offering costs (in shares)	49,000,003
Stock issued for cash, net of offering costs	$ 4,900	1,274,000	0	1,278,900
Share based compensation expense		6,500		6,500
Net income (loss)	$ 0	0	(313,057)	(313,057)
Balance (in shares) at Sep. 30, 2022	378,205,894
Balance at Sep. 30, 2022	$ 37,821	$ 104,160,079	$ (105,391,268)	$ (1,193,368)

Note 1 - Background and Signifi

Note 1 - Background and Significant Accounting Policies	6 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 1 GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned Canadian subsidiary, GbS Global Biopharma, Inc. (“GBSGB”). Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB’s assets include a portfolio of intellectual property containing both proprietary plant-inspired formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. The Company’s intellectual property portfolio, which is held by GBSGB, contains six three October 14th, 2021, Ph A R O S March 1st, 2022, TRPV1 GBSGB’s intellectual property covers a range of over 65 five first 19, Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2023. March 31, 2022 not 10 March 31, 2022 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. All subsidiaries were wholly owned by the Company for the periods presented. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Discontinued Operations See Note 3. Indefinite and Definite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. We amortize our finite-lived intangible assets, which consist of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. At September 30, 2022 six two four January 2038 May 2039. six September 30, 2022 2021 September 30, 2022 There were 18 United States patent applications that are pending as of September 30, 2022 September 30, 2022 September 30, 2022 Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source was part of discontinued operations prior to the sale of the Nevada Subsidiaries (Note 8 606, may may one 606 not Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company previously operated in the State-licensed cannabis industry through its now-deconsolidated Nevada Subsidiaries, gross profits from those subsidiaries was subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 172,235,838 and 162,197,658 potentially dilutive common shares, related to convertible debt, warrants, and stock options, at September 30, 2022 September 30, 2021 not three six September 30, 2022 2021 Recent Accounting Pronouncements Standards Recently Adopted In May 2021, No. 2021 04, 2021 04 April 1, 2022. April 1, 2022 not Standards Not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 2 - Going Concern

Note 2 - Going Concern	6 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 The Company’s unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $105,391,268 at September 30, 2022 September 30, 2022 March 31, 2022 six September 30, 2022 six September 30, 2021 Management has been able, thus far, to finance the losses through debt financings, a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not may

Note 3 - Discontinued Operation

Note 3 - Discontinued Operations	6 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Note 3 Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC (the "Nevada Subsidiaries") in discontinued operations due to the sale of the Company's Nevada cultivation and extraction facilities. The assets and liabilities of the Nevada Subsidiaries were deconsolidated at December 31, 2021 8 There were no assets and liabilities associated with discontinued operations as of September 30, 2022 March 31, 2022 three six September 30, 2021 For the Three Months Ended September 30, 2022 2021 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ - $ - $ - $ 1,215,995 $ 1,215,995 Cost of goods sold - - - - (1,020,913 ) (1,020,913 ) Gross profit - - - - 195,082 195,082 General and administrative expenses 275,839 - 275,839 411,545 108,790 520,335 INCOME/(LOSS) FROM OPERATIONS (275,839 ) - (275,839 ) (411,545 ) 86,292 (325,253 ) OTHER INCOME/(EXPENSE) Interest expense (37,218 ) - (37,218 ) (95,244 ) (100,911 ) (196,155 ) Other income - - - 9,000 - 9,000 Total other expense (37,218 ) - (37,218 ) (86,244 ) (100,911 ) (187,155 ) LOSS BEFORE INCOME TAXES (313,057 ) - (313,057 ) (497,789 ) (14,619 ) (512,408 ) Income tax expense - - - - (43,448 ) (43,448 ) NET LOSS $ (313,057 ) $ - $ (313,057 ) $ (497,789 ) $ (58,067 ) $ (555,856 ) For the Six Months Ended September 30, 2022 2021 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ - $ - $ - $ 2,558,581 $ 2,558,581 Cost of goods sold - - - - (2,239,954 ) (2,239,954 ) Gross profit - - - - 318,627 318,627 General and administrative expenses 735,357 - 735,357 904,951 192,868 1,097,819 INCOME/(LOSS) FROM OPERATIONS (735,357 ) - (735,357 ) (904,951 ) 125,759 (779,192 ) OTHER INCOME/(EXPENSE) Interest expense (75,789 ) - (75,789 ) (160,498 ) (203,242 ) (363,740 ) Other income - - - 9,000 20,891 29,891 Total other expense (75,789 ) - (75,789 ) (151,498 ) (182,351 ) (333,849 ) LOSS BEFORE INCOME TAXES (811,146 ) - (811,146 ) (1,056,449 ) (56,592 ) (1,113,041 ) Income tax expense - - - - (75,231 ) (75,231 ) NET LOSS $ (811,146 ) $ - $ (811,146 ) $ (1,056,449 ) $ (131,823 ) $ (1,188,272 )

Note 4 - Notes and Convertible

Note 4 - Notes and Convertible Notes Payable	6 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4 0% October 23, 2017 On March 4, 2022, At September 30, 2022 six September 30, 2022 March 2017 July 2017 In March 2017, third three March 2017 May 2017, three one three In July 2017, third three July 2017 December 2017, three one three All notes from the March July 2017 March 31, 2022, $197,000 three September 30, 2023. 10% six September 30, 2022 $197,000 September 30, 2022 Three convertible notes totaling $1,060,000 held by the same investor remained outstanding during the year ended March 31, 2022. January 20, 2022, $500k one "$560k three not September 28, 2022, "$560k $560k $560,000 October 1, 2023, $560k October 1, 2022. $129,534 $500k October 5, 2022 $500k At September 30, 2022 $560k October 1, 2023 six September 30, 2022 December 2020 $625,000 6% On December 18, 2020, 19 three January 31, 2022 July 1, 2022, December 2023. At September 30, 2022, $300,000 "$300k $25,000 "$25k January 18, 2022, $50,000 July 1, 2022 ( "$50k September 28, 2022, "$300k $300k October 1, 2023 October 1, 2022. $25k $50k not At September 30, 2022 six September 30, 2022 Summary of Notes and Convertible Notes Payable As of September 30, 2022 As of September 30, 2022 Face Value Discount Carrying Value 8% Note Payable dated October 23, 2017 (as amended), current portion $ 56,095 $ - $ 56,095 8% Convertible promissory note payable due October 1, 2023 560,000 - 560,000 8% Convertible note payable due October 1, 2023 300,000 - 300,000 6% Convertible notes payable due January 18, 2022 25,000 - 25,000 6% Convertible note payable due July 1, 2022 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 197,000 (18,176 ) 178,824 Total short-term notes and convertible notes payable $ 1,188,095 $ (18,176 ) $ 1,169,919 6% Convertible note payable due December 31, 2023 $ 250,000 $ (52,529 ) $ 197,471 8% Note Payable dated October 23, 2017 (as amended), long term portion 22,126 - 22,126 Total long term convertible notes payable classified as continuing operations $ 272,126 $ (52,529 ) $ 219,597

Note 5 - Capital Transactions

Note 5 - Capital Transactions	6 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 5 Sale of Common Stock and Warrants On May 9, 2022 one one one five September 9, 2022, November 30, 2022 six September 30, 2022 one five As the result of the units sold to date under the private placement, the Company will issue its brokers 5,316,834 compensation warrants to purchase one share of the Company's common stock at $0.03 per share for a period of five Employee Option Grant On August 25, 2022, seven one one

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	6 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 6 On April 11, 2022, May 2020. September 28, 2022. From time to time, the Company may not

Note 7 - Related Party Transact

Note 7 - Related Party Transactions	6 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 7 There were no six September 30, 2022

Note 8 - Sale of Membership Int

Note 8 - Sale of Membership Interests in Nevada Subsidiaries	6 Months Ended
	Sep. 30, 2022
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 8 On March 24, 2020, On August 10, 2020, 483 October 23, 2017 ( 4 The closing of the Teco and Nopah sales was contingent upon the successful transfer of the Nevada cultivation and production licenses. On December 14, 2021, December 31, 2021. As the result of sale, the income, assets, and cash flows of GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's consolidated financial statements prior to the sale. Note Receivable from Sale of Teco Subsidiaries The $3,025,000 note receivable from the sale of the Teco Subsidiaries is payable as quarterly, interest only payments of $60,500 for the first March 31, 2023, December 31, 2024. The note contains a provision that allows payments of principal and interest due prior to the maturity date to be postponed to the next quarterly payment date if cash flow from the operations of the facility is insufficient to cover the amount of the payment. Several days prior to the first April 1, 2022, April 1, 2022 July 1, 2022 March 31, 2022,

Note 9 - Subsequent Events

Note 9 - Subsequent Events	6 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	Note 9 On October 5, 2022, $500k 4

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2023. March 31, 2022 not 10 March 31, 2022
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. All subsidiaries were wholly owned by the Company for the periods presented.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations See Note 3.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Indefinite and Definite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. We amortize our finite-lived intangible assets, which consist of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. At September 30, 2022 six two four January 2038 May 2039. six September 30, 2022 2021 September 30, 2022 There were 18 United States patent applications that are pending as of September 30, 2022 September 30, 2022 September 30, 2022
Debt, Policy [Policy Text Block]	Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source was part of discontinued operations prior to the sale of the Nevada Subsidiaries (Note 8 606, may may one 606 not
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company previously operated in the State-licensed cannabis industry through its now-deconsolidated Nevada Subsidiaries, gross profits from those subsidiaries was subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E.
Earnings Per Share, Policy [Policy Text Block]	Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 172,235,838 and 162,197,658 potentially dilutive common shares, related to convertible debt, warrants, and stock options, at September 30, 2022 September 30, 2021 not three six September 30, 2022 2021
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Standards Recently Adopted In May 2021, No. 2021 04, 2021 04 April 1, 2022. April 1, 2022 not Standards Not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 3 - Discontinued Operati_2

Note 3 - Discontinued Operations (Tables)	6 Months Ended
	Sep. 30, 2022
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	For the Three Months Ended September 30, 2022 2021 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ - $ - $ - $ 1,215,995 $ 1,215,995 Cost of goods sold - - - - (1,020,913 ) (1,020,913 ) Gross profit - - - - 195,082 195,082 General and administrative expenses 275,839 - 275,839 411,545 108,790 520,335 INCOME/(LOSS) FROM OPERATIONS (275,839 ) - (275,839 ) (411,545 ) 86,292 (325,253 ) OTHER INCOME/(EXPENSE) Interest expense (37,218 ) - (37,218 ) (95,244 ) (100,911 ) (196,155 ) Other income - - - 9,000 - 9,000 Total other expense (37,218 ) - (37,218 ) (86,244 ) (100,911 ) (187,155 ) LOSS BEFORE INCOME TAXES (313,057 ) - (313,057 ) (497,789 ) (14,619 ) (512,408 ) Income tax expense - - - - (43,448 ) (43,448 ) NET LOSS $ (313,057 ) $ - $ (313,057 ) $ (497,789 ) $ (58,067 ) $ (555,856 ) For the Six Months Ended September 30, 2022 2021 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ - $ - $ - $ 2,558,581 $ 2,558,581 Cost of goods sold - - - - (2,239,954 ) (2,239,954 ) Gross profit - - - - 318,627 318,627 General and administrative expenses 735,357 - 735,357 904,951 192,868 1,097,819 INCOME/(LOSS) FROM OPERATIONS (735,357 ) - (735,357 ) (904,951 ) 125,759 (779,192 ) OTHER INCOME/(EXPENSE) Interest expense (75,789 ) - (75,789 ) (160,498 ) (203,242 ) (363,740 ) Other income - - - 9,000 20,891 29,891 Total other expense (75,789 ) - (75,789 ) (151,498 ) (182,351 ) (333,849 ) LOSS BEFORE INCOME TAXES (811,146 ) - (811,146 ) (1,056,449 ) (56,592 ) (1,113,041 ) Income tax expense - - - - (75,231 ) (75,231 ) NET LOSS $ (811,146 ) $ - $ (811,146 ) $ (1,056,449 ) $ (131,823 ) $ (1,188,272 )

Note 4 - Notes and Convertibl_2

Note 4 - Notes and Convertible Notes Payable (Tables)	6 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Debt [Table Text Block]	As of September 30, 2022 Face Value Discount Carrying Value 8% Note Payable dated October 23, 2017 (as amended), current portion $ 56,095 $ - $ 56,095 8% Convertible promissory note payable due October 1, 2023 560,000 - 560,000 8% Convertible note payable due October 1, 2023 300,000 - 300,000 6% Convertible notes payable due January 18, 2022 25,000 - 25,000 6% Convertible note payable due July 1, 2022 50,000 - 50,000 6% Convertible promissory notes payable due September 30, 2023 197,000 (18,176 ) 178,824 Total short-term notes and convertible notes payable $ 1,188,095 $ (18,176 ) $ 1,169,919 6% Convertible note payable due December 31, 2023 $ 250,000 $ (52,529 ) $ 197,471 8% Note Payable dated October 23, 2017 (as amended), long term portion 22,126 - 22,126 Total long term convertible notes payable classified as continuing operations $ 272,126 $ (52,529 ) $ 219,597

Note 1 - Background and Signi_2

Note 1 - Background and Significant Accounting Policies (Details Textual)	6 Months Ended
	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($) shares	Jun. 30, 2022	Mar. 31, 2022 USD ($)
Finite-Lived Intangible Assets, Net, Ending Balance	$ 2,238,971			$ 2,222,074
Indefinite-Lived Intangible Assets, Pending, Number	18
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares	172,235,838	162,197,658
Licensed Patents [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance	$ 943,667
Trademarks [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance	17,696
Patents [Member]
Amortization of Intangible Assets	40,492	$ 28,829
Finite-Lived Intangible Assets, Net, Ending Balance	$ 1,277,608
Patents [Member] | UNITED STATES
Finite-Lived Intangible Assets, Number	6
Patents [Member] | UNITED STATES | GBS Global Biopharma, Inc [Member]
Finite-Lived Intangible Assets, Number			4
Patents [Member] | Non-US [Member]
Finite-Lived Intangible Assets, Number	3
Patents Pending [Member] | UNITED STATES
Finite-Lived Intangible Assets, Number	18
Patents Pending [Member] | Non-US [Member]
Finite-Lived Intangible Assets, Number	49
Licensed Patents [Member] | UNITED STATES
Finite-Lived Intangible Assets, Number			2

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2022
Retained Earnings (Accumulated Deficit), Total	$ (105,391,268)		$ (104,580,122)
Working Capital (Deficit)	3,212,742		$ 3,607,638
Net Cash Provided by (Used in) Operating Activities, Total	(907,564)	$ (772,461)
Cash Provided by (Used in) Operating Activities, Discontinued Operations	$ 0	$ 16,243

Note 3 - Discontinued Operati_3

Note 3 - Discontinued Operations (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Discontinued Operations [Member]
Accounts Receivable, after Allowance for Credit Loss, Total	$ 0	$ 0

Note 3 - Discontinued Operati_4

Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Sales revenue	$ 0	$ 0	$ 0	$ 0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
General and administrative expenses	275,839	411,545	735,357	904,951
Interest expense	(37,218)	(95,244)	(75,789)	(160,498)
Other income	0	9,000	0	9,000
Total other expense	(37,218)	(86,244)	(75,789)	(151,498)
Income tax expense	0	0	0	0
NET LOSS	0	(58,067)	0	(131,823)
Continuing Operations [Member]
Sales revenue	0	0	0	0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
General and administrative expenses	275,839	411,545	735,357	904,951
INCOME/(LOSS) FROM OPERATIONS	(275,839)	(411,545)	(735,357)	(904,951)
Interest expense	(37,218)	(95,244)	(75,789)	(160,498)
Other income	0	9,000	0	9,000
Total other expense	(37,218)	(86,244)	(75,789)	(151,498)
LOSS BEFORE INCOME TAXES	(313,057)	(497,789)	(811,146)	(1,056,449)
Income tax expense	0	0	0	0
NET LOSS	(313,057)	(497,789)	(811,146)	(1,056,449)
Discontinued Operations [Member]
Sales revenue	0	1,215,995	0	2,558,581
Cost of goods sold	0	(1,020,913)	0	(2,239,954)
Gross profit	0	195,082	0	318,627
General and administrative expenses	0	108,790	0	192,868
INCOME/(LOSS) FROM OPERATIONS	0	86,292	0	125,759
Interest expense	0	(100,911)	0	(203,242)
Other income	0	0	0	20,891
Total other expense	0	(100,911)	0	(182,351)
LOSS BEFORE INCOME TAXES	0	(14,619)	0	(56,592)
Income tax expense	0	(43,448)	0	(75,231)
NET LOSS	0	(58,067)	0	(131,823)
Segment, Continuing and Discontinued Operations [Member]
Sales revenue	0	1,215,995	0	2,558,581
Cost of goods sold	0	(1,020,913)	0	(2,239,954)
Gross profit	0	195,082	0	318,627
General and administrative expenses	275,839	520,335	735,357	1,097,819
INCOME/(LOSS) FROM OPERATIONS	(275,839)	(325,253)	(735,357)	(779,192)
Interest expense	(37,218)	(196,155)	(75,789)	(363,740)
Other income	0	9,000	0	29,891
Total other expense	(37,218)	(187,155)	(75,789)	(333,849)
LOSS BEFORE INCOME TAXES	(313,057)	(512,408)	(811,146)	(1,113,041)
Income tax expense	0	(43,448)	0	(75,231)
NET LOSS	$ (313,057)	$ (555,856)	$ (811,146)	$ (1,188,272)

Note 4 - Notes and Convertibl_3

Note 4 - Notes and Convertible Notes Payable (Details Textual)			1 Months Ended			3 Months Ended	6 Months Ended			9 Months Ended	12 Months Ended
	Oct. 05, 2022 USD ($)	Mar. 04, 2022 USD ($)	Jan. 31, 2022 USD ($)	Jul. 31, 2017 USD ($) $ / shares	Mar. 31, 2017 USD ($) $ / shares	May 31, 2017 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 18, 2020 USD ($) $ / shares	Mar. 31, 2022 USD ($) $ / shares shares	Oct. 01, 2022	Sep. 28, 2022 USD ($)	Aug. 10, 2020
Amortization of Debt Discount (Premium)							$ 30,548	$ 104,499
Proceeds from Convertible Debt							0	$ 50,000
Convertible Notes Payable, Current							1,169,919				$ 987,565
Debt Instrument, Unamortized Discount, Current							18,176				1,765
Convertible Notes Payable, Noncurrent							219,597				397,308
Debt Instrument, Unamortized Discount, Noncurrent							52,529				$ 99,489
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants					4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 0.60	$ 0.60
Warrants and Rights Outstanding, Term (Year)					3 years	3 years
Class of Warrant or Right, Issued (in shares) | shares						8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares						1
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member]
Debt Instrument, Convertible, Number of Warrants				4,000
Class of Warrant or Right, Issued During Period (in shares) | shares											788,000
Warrants Related to July 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares				$ 0.65					$ 0.60
Warrants and Rights Outstanding, Term (Year)									3 years
Class of Warrant or Right, Issued (in shares) | shares									28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares									1
Warrants Issued in September 30, 2023, Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares											$ 0.10
Warrants and Rights Outstanding, Term (Year)											3 years
Warrants and Rights Outstanding											$ 13,396
March 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage					6%
Debt Instrument, Face Amount Per Note					$ 1,000
Debt Instrument, Face Amount						$ 2,000,000
Debt Instrument, Term (Year)						3 years
Debt Instrument, Unamortized Discount, Total						$ 1,933,693
Debt Instrument, Convertible, Beneficial Conversion Feature						904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants						$ 1,029,003
March 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments					4,000	8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares					$ 0.25
July 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member]
Debt Instrument, Face Amount Per Note				$ 1,000
Debt Instrument, Face Amount									$ 7,201,000
Debt Instrument, Term (Year)				3 years					3 years
Debt Instrument, Unamortized Discount, Total									$ 7,092,796
Debt Instrument, Convertible, Beneficial Conversion Feature									3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants									$ 3,950,191
July 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments				4,000					28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 0.25
July 2017 Convertible Note Offering [Member] | Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage				6%
March And July 2017 Convertible Note Offering [Member] | Convertible Notes Payable [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares											$ 0.10
Debt Instrument, Extended Amount											$ 197,000
Convertible Notes Payable, Total											1,257,000
The 6 % Convertible Note Payable Dated December 31, 2023 [Member]
Debt Instrument, Interest Rate, Stated Percentage										6%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares										$ 0.05
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount										$ 625,000
The 6 % Convertible Note Payable Mature in December 2021 [Member] | Three Investors [Member]
Debt Instrument, Face Amount										375,000
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount										250,000
The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member]
Debt Instrument, Face Amount										425,000
Debt Instrument, Unamortized Discount, Total										81,250
Debt Instrument, Convertible, Beneficial Conversion Feature										347,000
Interest Expense, Debt, Total							41,273
Amortization of Debt Discount (Premium)							28,785
Proceeds from Convertible Debt										$ 543,750
Convertible Notes Payable, Current							375,000
Debt Instrument, Unamortized Discount, Current							0
Convertible Notes Payable, Noncurrent							197,471
Debt Instrument, Unamortized Discount, Noncurrent							52,529
The 300k Extension [Member]
Convertible Notes Payable, Total													$ 300,000
The 300k Extension [Member] | Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage												8%
Promissory Note [Member]
Debt Instrument, Face Amount							272,126
Debt Instrument, Unamortized Discount, Noncurrent							52,529
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Notes Payable, Principal and Interest		$ 201,532
Notes Payable, Principal and Interest, After Modified Terms		179,127
Repayments of Notes Payable		75,000					15,000
Debt Instrument, Periodic Payment, Total		$ 5,000
Debt Instrument, Interest Rate, Stated Percentage		8%												0%
Notes Payable, Total							78,221
Interest Payable							189
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total							1,984
Extinguishment of Debt, Amount							13,016
Convertible Debt [Member]
Interest Payable			$ 294,497
Convertible Notes Payable, Total											1,060,000
Convertible Debt [Member] | March And July 2017 Convertible Note Offering [Member]
Interest Payable											59,099
Debt Instrument, Unamortized Discount, Total							22,318				46,886
Debt Instrument, Convertible, Beneficial Conversion Feature											$ 33,490
Interest Expense, Debt, Total							6,883
Amortization of Debt Discount (Premium)							3,936
Convertible Debt [Member] | The 500K Note [Member]
Repayments of Convertible Debt			500,000
Convertible Debt [Member] | The 500K Note [Member] | Subsequent Event [Member]
Interest Payable	$ 0
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total	129,534
Convertible Notes Payable, Total	$ 0
Convertible Debt [Member] | The 560k Extension [Member]
Interest Payable							173,432
Convertible Notes Payable, Total			$ 560,000										$ 560,000
Interest Expense, Debt, Total							$ 16,846
Convertible Debt [Member] | The 560k Extension [Member] | Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage												8%

Note 4 - Notes Payable and Line

Note 4 - Notes Payable and Line of Credit - Summary of Notes and Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2022	Mar. 31, 2022
Discount, short-term notes payable	$ (18,176)	$ (1,765)
Discount, long-term notes payable	(52,529)	$ (99,489)
Promissory Note [Member]
Debt instrument, face amount	272,126
Discount, long-term notes payable	(52,529)
Carrying value, long-term notes payable	219,597
Promissory Note, Short Term [Member]
Debt instrument, face amount	1,188,095
Carrying value, short-term notes payable	1,169,919
Discount, short-term notes payable	(18,176)
The 8% Note Payable Dated October 23, 2017, Current Portion [Member] | Short Term Note Payable [Member]
Debt instrument, face amount	56,095
Carrying value, short-term notes payable	56,095
The 8% Convertible Promissory Note Payable Due October 1, 2023 [Member] | Convertible Debt [Member]
Debt instrument, face amount	560,000
Carrying value, short-term notes payable	560,000
The 8% Convertible Notes Payable October 1, 2023 [Member] | Convertible Debt [Member]
Debt instrument, face amount	300,000
Carrying value, short-term notes payable	300,000
The 6% Notes Payable Due January 18, 2022 [Member] | Convertible Debt [Member]
Debt instrument, face amount	25,000
Carrying value, short-term notes payable	25,000
The 6% Notes Payable Due July 1, 2022 [Member] | Convertible Debt [Member]
Debt instrument, face amount	50,000
Carrying value, short-term notes payable	50,000
The 6 % Note Payable Dated September 30, 2023 [Member] | Convertible Debt [Member]
Debt instrument, face amount	197,000
Carrying value, short-term notes payable	178,824
Discount, short-term notes payable	(18,176)
The 6% Convertible Note Payable Due December 31, 2023 [Member] | Convertible Long-term Debt [Member]
Debt instrument, face amount	250,000
Discount, long-term notes payable	(52,529)
Carrying value, long-term notes payable	197,471
The 8% Note Payable Dated October 23, 2017, Long Term Portion [Member] | Note Payable [Member]
Debt instrument, face amount	22,126
Carrying value, long-term notes payable	$ 22,126

Note 5 - Capital Transactions (

Note 5 - Capital Transactions (Details Textual) - USD ($)			6 Months Ended
	Sep. 09, 2022	May 09, 2022	Sep. 30, 2022	Aug. 25, 2022	Jun. 30, 2022
Proceeds from Issuance of Private Placement			$ 1,387,650
Share-Based Payment Arrangement, Option [Member] | Seven Persons [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Authorized, Percentage of Common Shares Issued and Outstanding				13%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price, Percentage of Value Per Share				80%
Warrants Issued to Investors in Private Placements [Member]
Number of Warrant Received, Per Unit (in shares)		1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.10	$ 0.10
Warrants and Rights Outstanding, Term (Year)			5 years		5 years
Class of Warrant or Right, Issued During Period (in shares)			53,168,337
Compensation Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.03
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, Issued During Period (in shares)			5,316,834
Class of Warrant or Right, Fair Value Assumption, Exercise Price (in dollars per share)			$ 0.0273
Private Placement [Member]
Sale of Units, Maximum Units Allowed in Private Placement	$ 2,000,000	$ 565,000
Sale of Units, Price Per Unit (in dollars per share)		$ 0.03
Number of Common Stock Received, Per Unit (in shares)		1
Brokerage Fees for Issuance of Common Stock and Warrants			$ 207,350
Stock Issued During Period, Shares, New Issues (in shares)			53,168,337

Note 6 - Commitments and Cont_2

Note 6 - Commitments and Contingencies (Details Textual)	Sep. 28, 2022 USD ($)
Maximum [Member]
Liability Insurance, Amount Per Occurrence	$ 1,000,000

Note 8 - Sale of Membership I_2

Note 8 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual)					6 Months Ended	12 Months Ended	18 Months Ended
	Dec. 31, 2021 USD ($)	Aug. 10, 2020 USD ($)	Mar. 24, 2020 USD ($)	Nov. 27, 2019	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Mar. 04, 2022
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage		0%							8%
Extinguishment of Debt, Amount					$ 13,016
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership				100%
Noncash or Part Noncash Divestiture, Amount of Consideration Received		$ 312,315
Nevada Subsidiaries [Member]
Sale of Stock, Percentage of Ownership			100%
Teco Subsidiaries [Member]
Sale of Stock, Consideration Received on Transaction			$ 8,000,000
Notes Receivable, Interest Rate			8%
GB Sciences Nopah, LLC [Member]
Notes Reduction		237,668
Sale of Stock, Percentage of Ownership before Transaction	100%
Sale of Stock, Percentage of Ownership after Transaction	0%
Financing Receivable, after Allowance for Credit Loss, Total	$ 3,025,000
Note Receivable, Interest Only, Monthly							$ 60,500
Quarterly Interest Only Payments on Note Receivable, Years					1		1	1
Number of Quarterly Principal and Interest Payments on Note Receivable					7		7	7
Note Receivable, Quarterly Principal and Interest Installment						$ 201,774
Final Payment, Principal and Interest Payments Due on Note Receivable					$ 2,014,225		$ 2,014,225	$ 2,014,225
Asset Impairment Charges, Total								$ 3,025,000
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member]
Extinguishment of Debt, Amount		$ 74,647

Note 9 - Subsequent Events (Det

Note 9 - Subsequent Events (Details Textual)	Oct. 05, 2022 USD ($)
Convertible Debt [Member] | The 500K Note [Member] | Subsequent Event [Member]
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total	$ 129,534